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INTRODUCTION 
1, 3, 4-Oxadiazoles are biologically active, synthetically 
useful and important heterocyclic compounds. Different 
classes of oxadiazole compounds possess an extensive 
spectrum of pharmacological activities such as 
antibacterial1, antimalarial2, anti-inflammatory3, 
antifungal4, anticonvulsant5, analgesic6 
antimycobacterial7, antitumor8, herbicidal9, 
vasodialatory10, cytotoxic11, hypolipidemic12, 
ulcerogenic13 and antiedema14. Numerous thiazolidinone 
derivatives have shown significant pharmacological and 
biological activities15 like sedative16, anti-
inflammatory17, antibacterial18, antifungal19, 
antitubercular20, anticancer21, hypnotic22, anti-HIV23 and 
nematicidal24.  
ANTIMICROBIAL ACTIVITY 
The in vitro antimicrobial activity of newly synthesized 
compounds, 4-phenyl-9-(5-phenyl-[1,3,4]-oxadiazol-2-
yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-diones 
(4a-e) was determined using disc diffusion method6. The 
antibacterial activity was measured against two gram-
positive strains viz., Staphylococcus aureus and Bacillus 
subtilis and two gram-negative strains viz., Escherichia 
coli and Pseudomonas aeruginosa and expressed in 
terms of zone of inhibition in mm at concentration of 5 
μg/disc. The antifungal evaluation was carried out 
against fungal organisms namely Candida albicans and 
Aspergillus niger at concentration of 5 μg/disc. Standard 
antibacterial drug Ciprofloxacin (5 μg/disc) and 
antifungal drug Fluconazole (5 μg/disc) were also tested 
under similar conditions against these organisms. Each 
experiment was done in triplicate and the average 
reading was taken. 
 
 
Scheme 1: 3, 4 Ar a) = C6H5, b) = 4-CH3-C6H4, c) = 4-OCH3-C6H4, d) = 4-Cl-C6H4, e) = 4-Br-C6H4 
ABSTRACT: 
A novel series of  4-phenyl-9-(5-phenyl-[1,3,4-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-diones (4a-e) in 
good to excellent yields by using commercially available 2-amino-5-phenyl-1,3,4-oxadiazole (1) as raw material and 2-chloro-
N-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-acetamide (2) and  2-benzylidene-3-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-thiazolidin-4-onea 
(3a-e) as intermediates. The chemical structures of these compounds have been established by IR, 1H, 13C-NMR, Mass spectral 
data and elemental analysis. The newly synthesized compounds were screened for their ability towards antimicrobial activity.  
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The investigation of antibacterial screening data revealed 
that all the tested compounds exhibited significant and 
interesting biological activity, however with a degree of 
variation. According to the results (Table 1), it is clear 
that, some of the compounds displayed excellent 
antimicrobial activity. Among the series of the screened 
compounds 4a-e, the compound 4e which contain 4-
bromo phenyl ring system, against E. coli is highly active 
at 28 mm zone of inhibition which is equal to the 
standard drug Ciproflaxacin.  The compound 4e towards 
C. albicans is also exhibited good antifungal activity at 
24 mm zone of inhibition which is almost equal to the 
standard drug. The remaining compounds showed 
moderate to good activity against the test organisms. It is 
interesting to note that, none of the compound is inactive 
against all the tested microorganisms and this remarkable 
property may achieve to the compounds due to the two 
active pharmacophores (oxadiazole and thiazole) in a 
single molecular skeleton.  
 
Table 1 Antimicrobial activity of compounds 4a-e (Zone of inhibition in mm) 
Compound                                Antibacterial activity                             Antifungal activity 
                         S. aureus     B. subtilis       E. coli     P. aeruginosa    C. albicans     A. niger  
4a    12                20                 13                 19                      12                 12 
4b                           11                18                 10                 14                      13                 10 
4c                           14                12                 18                 12                      15                 16 
4d                           20                21                 26                 20                      19                 20 
4e                           24                23                 28                 20                      24                 22 
Ciprofloxacin        26                26                 28                 25                      ―                 ― 
Fluconazole           ―                ―                 ―                 ―                      26                 25 
 
EXPERIMENTAL 
All reagents and solvents were used as purchased 
without further purification. Melting points were 
determined on a Fisher–Johns melting point apparatus 
and are uncorrected. Crude products were purified by 
column chromatography on silica gel of 60–120 mesh. 
IR spectra were obtained on a PerkinElmer BX series 
FT-IR 5000 spectrometer using KBr pellet. NMR spectra 
were recorded on a Varian 300 MHz spectrometer for 1H 
NMR. The chemical shifts were reported as ppm down 
field using TMS as an internal standard. Mass spectra 
were recorded on a VG-Micromass 7070H spectrometer 
operating at 70 eV. 
Synthesis of 2-chloro-N-(5-phenyl-[1,3,5]-oxadiazol-2-
yl)-acetamide (2) 
A mixture of 2-amino, 5-phenyl-1,3,4-oxadiazole (1) 
(0.01 mol) and chloroacetyl chloride  (0.01 mol) was 
refluxed in triethyl amine (10 ml) for 4 h. After 
completion of the reaction (monitored by TLC), the 
resultant solution was cooled, the separated solid was 
filtered, dried and recrystallised from pet-ether to get 
pure 2-chloro-N-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-
acetamide (2). 
Synthesis of 2-benzylidene-3-(5-phenyl-[1,3,5]-
oxadiazol-2-yl)-thiazolidin-4-one (3)  
Compound 2 (0.01 mol) was treated with phenyl 
isocyanate (0.01 mol) at room temperature in presence of 
K2CO3 (0.5 g) in acetonitrile (15 ml). The reaction 
mixture was refluxed on constant stirring for 6 h. After 
conventional work up, the product was purified by 
recrystallization from methanol to give pure 2-
benzylidene-3-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-
thiazolidin-4-one (3). 
Synthesis of 4-phenyl-9-(5-phenyl-[1,3,4]-oxadiazol-2-
yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-dione 
(4a-e) 
An equimolar mixture of compound 3 (0.01 mol) and 
mercapto acetic acid (0.01 mol) was refluxed in dioxane 
for 7-9 h. After completion of the reaction (monitored by 
TLC), the reaction mixture was allowed to cool and was 
poured over crushed ice. The organic layer was extracted 
with ethyl acetate (20 ml), washed with 10% sodium 
bicarbonate solution (1 X 20 ml) and dried with 
anhydrous sodium sulphate. The solvent was removed 
under vacuum and residue was recrystallized from 
methanol to yield the corresponding 4-phenyl-9-(5-
phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-
spiro-[4.4]-nonane-3,8-dione (4a-e). 
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PHYSICAL AND SPECTRAL DATA 
2-Chloro-N-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-acetamide (2) 
White solid; Yield 74%; Mp 155-157 0C; IR (KBr) 3316 (N-H), 3024 (C-H, Ar), 2965 (C-H), 1680 (C=O), 1640 (C=N) 
1560 (C=C, Ar) cm-1; 1H NMR (300 MHz, CDCl3) δ 4.21 (s, 2H, CH2), 7.12-7.69 (m, 5H, Ar-H), 7.16 (s, 1H, NH); 
13C 
NMR (100 MHz, CDCl3) δ 165.7, 159.3, 147.2, 137.2, 134.6, 131.8 (2), 125.7 (2), 45.8; MS m/z 237 (M
+); Elemental 
analysis: Calculated for C10H8ClN3O2: C-50.54, H-3.39, Cl-14.92, N-17.68, O-13.47. Found: C-48.23, H-3.12, Cl-
13.68, N-16.45, O-12.78. 
2-Benzylidene-3-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-thiazolidin-4-one (3a) 
Yellow solid; Yield 72%; Mp 163-165 0C; IR (KBr) 3035 (C-H, Ar), 1690 (C=O), 1630 (C=N), 1568 (C=C, Ar) cm-1; 
1H NMR (300 MHz, CDCl3) δ
 4.26 (s, 2H, CH2), 6.98-7.89 (m, 10H, Ar-H); 
13C NMR (100 MHz, CDCl3) δ 164.8, 
161.3, 160.4, 144.8, 136.1, 134.2, 132.8, 130.6 (2), 129.3 (2), 126.8 (2), 125.3, 124.7 (2), 38.1; MS m/z 336 (M+); 
Elemental analysis: Calculated for C17H12N4O2S: C-60.70, H-3.60, N-16.66, O-9.51, S-9.53. Found: C-58.79, H-3.32, 
N-15.64, O-8.67, S-8.74. 
2-(4-Methyl-benzylidene)-3-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-thiazolidin-4-one (3b) 
Pale yellow solid; Yield 76%; Mp 132-134 0C; IR (KBr) 3041 (C-H, Ar), 2945 (C-H, CH3), 1685 (C=O), 1642 (C=N), 
1610 (C=C) cm-1; 1H NMR (300 MHz, CDCl3) δ
 2.43 (s, 3H, CH3), 4.26 (s, 2H, CH2), 7.01-7.87 (m, 5H, Ar-H), 7.33 
(d, 2H, J = 7.4 Hz, ArH), 7.45 (d, 2H, J = 7.4 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ 164.3, 160.8, 156.7, 149.2, 
137.4, 135.3, 133.2, 132.7, 131.8 (2), 130.8, 129.4 (2), 126.7 (2), 124.9, 38.2, 22.6; MS m/z 350 (M+); Elemental 
analysis: Calculated for C18H14N4O2S: C-61.70, H-4.03, N-15.99, O-9.13, S-9.15. Found: C-59.64, H-3.94, N-14.85, O-
8.69, S-8.74. 
2-(4-Methoxy-benzylidene)-3-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-thiazolidin-4-one (3c) 
Orange solid; Yield 71%; Mp 160-162 0C; IR (KBr) 3038 (C-H, Ar), 2928 (C-H, CH3), 1685 (C=O), 1635 (C=N), 1575 
(C=C) cm-1; 1H NMR (300 MHz, CDCl3) δ
 3.72 (s, 3H, OCH3), 4.10 (s, 2H, CH2), 7.15-7.69 (m, 5H, Ar-H), 7.42 (d, 
2H, J = 7.2 Hz, ArH), 7.54 (d, 2H, J = 7.2 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ 163.2, 161.8, 158.6, 155.3, 151.7, 
146.4, 135.3, 134.2, 132.4, 130.7 (2), 128.6 (2), 125.8, 114.8 (2), 58.6, 23.7; MS m/z 366 (M+); Elemental analysis: 
Calculated for C18H14N4O3S: C-59.01, H-3.85, N-15.29, O-13.10, S-8.75. Found: C-57.62, H-3.27, N-14.39, O-12.86, 
S-7.95. 
2-(4-Chloro-benzylidene)-3-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-thiazolidin-4-one (3d) 
Brown solid; Yield 73%; Mp 150-152 0C; IR (KBr) 3028 (C-H, Ar), 1695 (C=O), 1630 (C=N), 1584 (C=C) cm-1; 1H 
NMR (300 MHz, CDCl3) δ
 4.21 (s, 2H, CH2), 7.09-7.54 (m, 5H, Ar-H), 7.39 (d, 2H, J = 7.0 Hz, ArH), 7.56 (d, 2H, J = 
7.0 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ 163.5, 160.8, 158.7, 151.0, 143.7, 133.8, 131.2, 130.7, 129.4 (2), 128.7, 
127.6 (2), 125.4 (2), 123.6, 35.7; MS m/z 370 (M+); Elemental analysis: Calculated for C17H11ClN4O2S: C-55.06, H-
2.99, Cl-9.56, N-15.11, O-8.63, S-8.65. Found: C-53.84, H-2.27, Cl-8.72, N-14.39, O-7.86, S-7.84. 
2-(4-Bromo-benzylidene)-3-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-thiazolidin-4-one (3e) 
Pale yellow solid; Yield 74%; Mp 144-146 0C; IR (KBr) 3032 (C-H, Ar), 1680 (C=O), 1631 (C=N), 1578 (C=C) cm-1; 
1H NMR (300 MHz, CDCl3) δ
 3.98 (s, 2H, CH2), 7.12-7.68 (m, 5H, Ar-H), 7.42 (d, 2H, J = 7.4 Hz, ArH), 7.74 (d, 2H, 
J = 7.4 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ 167.7, 161.6, 159.6, 156.7, 149.2, 135.3, 1342, 133.7, 132.8 (2), 
131.7, 130.5 (2), 126.7 (2), 124.9, 38.2, MS m/z 415 (M+); Elemental analysis: Calculated for C17H11BrN4O2S: C-49.17, 
H-2.67, Br-19.24, N-13.49, O-7.71, S-7.72. Found: C-47.36, H-2.32, Br-17.46, N-12.39, O-6.94, S-6.84. 
4-Phenyl-9-(5-phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-dione (4a) 
Brown solid; Yield 70%; Mp 170-172 0C; IR (KBr) 3048 (C-H, Ar), 1710 (C=O), 1634 (C=N), 1610 (C=C, Ar), 1275 
(C-S) cm-1; 1H NMR (300 MHz, CDCl3) δ
 4.18 (s, 2H, CH2), 4.41 (s, 2H, CH2), 7.12-7.69 (m, 10H, Ar-H); 
13C NMR 
(100 MHz, CDCl3) δ  167.5, 164.8, 153.2, 144.6, 141.6, 137.4, 131.8 (2), 129.7, 127.6 (2), 126.3 (2), 123.4, 121.7 (2), 
76.4, 32.0, 28.6; MS m/z 410 (M+); Elemental analysis: Calculated for C19H14N4O3S2: C-55.60, H-3.44, N-13.65, O-
11.69, S-15.62. Found: C-54.36, H-3.14, N-12.95, O-10.74, S-14.82. 
4-(5-Phenyl-[1,3,4]-oxadiazol-2-yl)-9-p-tolyl-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-dione (4b) 
Yellow solid; Yield 77%; Mp 140-142 0C; IR (KBr) 3036 (C-H, Ar), 1710 (C=O), 1634 (C=N), 1623 (C=C), 1285 (C-
S) cm-1; 1H NMR (300 MHz, CDCl3) δ
 2.39 (s, 3H, CH3), 4.21 (s, 2H, CH2), 4.28 (s, 2H, CH2), 7.12-7.59 (m, 5H, Ar-
H), 7.42 (d, 2H, J = 7.4 Hz, ArH), 7.68 (d, 2H, J = 7.4 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ  165.6, 162.7, 155.4, 
146.7, 143.0, 139.4, 134.2, 132.6 (2), 130.2, 127.6 (2), 125.8 (2), 120.9 (2), 74.8, 30.7, 26.4, 22.7; MS m/z 424 (M+); 
Elemental analysis: Calculated for C20H16N4O3S2: C-56.59, H-3.80, N-13.20, O-11.31, S-15.11. Found: C-54.95, H-
3.25, N-12.94, O-10.85, S-14.67. 
4-(4-Methoxy-phenyl)-9-(5-phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-dione (4c) 
Orange solid; Yield 71%; Mp 120-122 0C; IR (KBr) 3038 (C-H, Ar), 1720 (C=O),1642 (C=N), 1624 (C=C), 1280 (C-
S) cm-1; 1H NMR (300 MHz, CDCl3) δ 3.95 (s, 3H, OCH3), 4.06 (s, 2H, CH2), 4.19 (s, 2H, CH2), 7.21-7.78 (m, 5H, Ar-
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H), 7.51 (d, 2H, J = 7.0 Hz, ArH), 7.65 (d, 2H, J = 7.0 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ  166.3, 163.2, 154.8, 
146.7, 143.7, 139.6, 136.7, 134.5 (2), 132.7 (2), 130.2, 128.7 (2), 123.4 (2), 78.7, 30.3, 26.3, 21.7; MS m/z 440 (M+); 
Elemental analysis: Calculated for C20H16N4O4S2: C-54.53, H-3.66, N-12.72, O-14.53, S-14.56. Found: C-52.68, H-
3.21, N-11.95, O-13.64, S-13.74. 
4-(4-Chloro-phenyl)-9-(5-phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-dione (4d) 
Yellow solid; Yield 70%; Mp 132-134 0C; IR (KBr) 3051 (C-H, Ar), 1648 (C=N), 1715 (C=O), 1623 (C=C),1270 (C-
S) cm-1; 1H NMR (300 MHz, CDCl3) δ
 4.18 (s, 2H, CH2), 4.25 (s, 2H, CH2), 7.12-7.59 (m, 5H, Ar-H), 7.42 (d, 2H, J = 
7.8 Hz, ArH), 7.65 (d, 2H, J = 7.8 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ  166.3, 163.2, 151.7, 142.8, 138.7, 135.4, 
131.7 (2), 129.6, 128.7 (2), 127.2, 125.3 (2), 119.8 (2), 73.7, 35.4, 29.7; MS m/z 444 (M+); Elemental analysis: 
Calculated for C19H13ClN4O3S2: C-51.29, H-2.95, Cl-7.97, N-12.59, O-10.79, S-14.41. Found: C-49.36, H-2.24, Cl-
6.98, N-11.94, O-9.94, S-13.75. 
4-(4-Bromo-phenyl)-9-(5-phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-dione (4e) 
Orange solid; Yield 73%; Mp 114-116 0C; IR (KBr) 3048 (C-H, Ar), 1720 (C=O),1660 (C=N), 1625 (C=C), 1275 (C-
S) cm-1; 1H NMR (300 MHz, CDCl3) δ
 4.15 (s, 2H, CH2), 4.26 (s, 2H, CH2), 7.18-7.58 (m, 5H, Ar-H), 7.39 (d, 2H, J = 
7.8 Hz, ArH), 7.68 (d, 2H, J = 7.8 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ  162.7, 160.7, 151.8, 140.6, 138.9, 135.7, 
132.8 (2), 129.8 (2), 126.8, 123.7 (2), 120.1 (2), 119.3, 78.7, 36.3, 30.2; MS m/z 487 (M+); Elemental analysis: 
Calculated for C19H13BrN4O3S2: C-46.63, H-2.68, Br-16.33, N-11.45, O-9.81, S-13.10. Found: C-44.39, H-2.31, Br-
15.64, N-10.75, O-9.28, S-12.46. 
 
RESULTS AND DISCUSSION 
The therapeutic importance of these rings prompted us to 
develop selective molecules in which a substituent could 
be arranged in a pharmacophoric pattern to display 
higher pharmacological activities. Thus we have 
designed and synthesized a series of novel 4-phenyl-9-
(5-phenyl-[1,3,4-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-
spiro-[4.4]-nonane-3,8-dione (4) in good to excellent 
yields by using commercially available 2-amino-5-
phenyl-1,3,4-oxadiazole (1). The synthetic route leading 
to the title compounds is summarized in scheme 1.  
The initial intermediate, 2-chloro-N-(5-phenyl-[1,3,5]-
oxadiazol-2-yl)-acetamide (2) was prepared through 
dehydrohalogenation between compound 1 and 
chloroacetyl chloride in triethyl amine under reflux for 4 
h. Compound 2 on cyclization with various phenyl 
thioisocyanates in presence of potassium carbonate in 
refluxing acetonitrile for 6 h to get the corresponding 
intermediate, 2-benzylidene-3-(5-phenyl-[1,3,5]-
oxadiazol-2-yl)-thiazolidin-4-one (3a-e). The title 
compounds 4-phenyl-9-(5-phenyl-[1,3,4-oxadiazol-2-yl)-
1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-diones (4a-e) 
have been prepared from the subsequent ring closure 
reaction of compound 3 with mercapto acetic acid in 
refluxing 1,4-diaxane for 7-9 h. The chemical structures 
of all the newly synthesized compounds were confirmed 
by their IR, 1H, 13C NMR, mass spectral data and 
elemental analysis. Further the compounds 4a-e were 
used to evaluate their antimicrobial activity. 
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